Metformin

People with type 2 diabetes who maintain low glycated haemoglobin levels have slower progression of frailty over time than those with higher levels, shows an analysis of Look AHEAD participants.

Metformin use is associated with a significant reduction in the risk for total knee or hip replacement among people with type 2 diabetes, shows research published in CMAJ.

People aged 60 years or older receiving thiazolidinedione monotherapy for type 2 diabetes may have a lower risk for dementia than those taking metformin monotherapy, an observational study suggests.

The authors of a modeling study say that the price of SGLT2 inhibitors and GLP-1 receptor agonists would need to fall “by at least 70%” for them to be cost effective as first-line treatments in the USA.

People with type 2 diabetes and chronic kidney disease are substantially less likely to initiate SGLT2 inhibitors than those with normal kidney function, despite their proven renoprotective benefits, research shows.

Clinicians are only rarely monitoring vitamin B12 levels in people with type 2 diabetes using metformin, research shows.

People with impaired glucose tolerance who received metformin or intensive lifestyle intervention during the DPP trial show no sign of a significantly reduced cardiovascular disease risk 21 years later, reveal the latest DPPOS results.

People who start SGLT2 inhibitors as a first-line diabetes treatment have a reduced risk for heart failure hospitalization relative to those who start metformin and a similar risk for other vascular outcomes, a study shows.

People with type 2 diabetes who have suboptimal glycemic control on metformin alone may benefit from add-on treatment with the dual-acting glucokinase activator dorzagliatin, report the DAWN investigators.

The proportion of individuals receiving second-line therapy for diabetes has decreased over time despite worsening glycemic control over the same period, US study findings indicate.

The risk for a birth defect may be increased if the father is taking metformin around the time of spermatogenesis, say researchers.

The proportion of on-target interstitial glucose values falls during the week following initial COVID-19 vaccination in people with type 1 diabetes, study findings indicate.

Initiating metformin following hospitalization for heart failure may reduce the risk for death or further HHF in older people with comorbid diabetes, but only if they have a preserved ejection fraction, study findings indicate.

The addition of liraglutide rather than extra oral antidiabetic drugs may offer more sustained glycemic control for people with type 2 diabetes who have inadequate control with metformin, suggest findings of the international LIRA-PRIME study.

Findings from the SoliMix trial indicate that iGlarLixi may improve glycemic control with weight benefit compared with BIAsp 30 among people with suboptimally controlled type 2 diabetes on basal insulin.

Findings from the TriMaster trial suggest that stratification of people with type 2 diabetes based on clinical features may help to guide the choice of second- or third-line drug for those who require treatment intensification after metformin.

Post-hoc analysis of the VERTIS-CV trial indicates that the cardiovascular effects of ertugliflozin are unaffected by whether people are also taking metformin.

Early achievement of a glycated hemoglobin (HbA1c) level below 7% is a key factor in maintaining long-term glucose control in people with type 2 diabetes initiating second-line glucose-lowering therapy, DISCOVER study data show.

Findings from the GRADE study, a head-to-head comparison of four commonly used diabetes drugs given together with metformin, suggest that liraglutide and insulin may result in better glycemic control than glimepiride and sitagliptin among people with type 2 diabetes.

Combining metformin with a sulfonylurea produces poorer non-glycemic outcomes than combining it with other second-line agents, show results from the global DISCOVER program.